Evotec SE (STU:EVT) E10: €-0.10 (As of Mar. 2026)


STU:EVT Evotec SE STU:EVT
65 GF Score
Price €4.85
GF Value €7.54
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE E10?

Evotec SE STU:EVT +1.29% 65 E10 is €-0.10 as of Mar. 2026. GuruFocus rates STU:EVT with a GF Score™ of 65/100 and a GF Value™ of €7.54 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Evotec SE's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.690. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.10 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Evotec SE's average E10 Growth Rate was -433.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Evotec SE was 84.20% per year. The lowest was -41.50% per year. And the median was 12.30% per year.

As of today (2026-06-28), Evotec SE's current stock price is €4.852. Evotec SE's E10 for the quarter that ended in Mar. 2026 was €-0.10. Evotec SE's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Evotec SE was 592.25. The lowest was 55.53. And the median was 150.40.


Evotec SE  (STU:EVT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Evotec SE was 592.25. The lowest was 55.53. And the median was 150.40.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Evotec SE E10 Related Terms


Evotec SE E10 Historical Data

* Premium members only.

The historical data trend for Evotec SE's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE E10 Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.17 0.15 0.05 -0.03

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 -0.01 -0.03 -0.03 -0.10

STU:EVT vs ZTS, UTHR, VTRS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's Shiller PE Ratio falls into.


STU:EVT
65GF Score
Evotec SE STU:EVT
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evotec SE's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.69/131.2583*131.2583
=-0.690

Current CPI (Mar. 2026) = 131.2583.

Evotec SE Quarterly Data

per share eps CPI Adj_EPS
201606 0.030 100.717 0.039
201609 0.070 101.017 0.091
201612 0.110 101.217 0.143
201703 0.050 101.417 0.065
201706 0.020 102.117 0.026
201709 0.020 102.717 0.026
201712 0.070 102.617 0.090
201803 0.020 102.917 0.026
201806 0.100 104.017 0.126
201809 0.230 104.718 0.288
201812 0.210 104.217 0.264
201903 0.090 104.217 0.113
201906 -0.020 105.718 -0.025
201909 0.130 106.018 0.161
201912 0.050 105.818 0.062
202003 0.110 105.718 0.137
202006 -0.070 106.618 -0.086
202009 -0.010 105.818 -0.012
202012 0.000 105.518 0.000
202103 0.320 107.518 0.391
202106 0.370 108.486 0.448
202109 0.820 109.435 0.984
202112 -0.200 110.384 -0.238
202203 -0.410 113.968 -0.472
202206 -0.160 115.760 -0.181
202209 -0.270 118.818 -0.298
202212 -0.150 119.345 -0.165
202303 -0.080 122.402 -0.086
202306 -0.080 123.140 -0.085
202309 -0.220 124.195 -0.233
202312 -0.091 123.773 -0.097
202403 -0.120 125.038 -0.126
202406 -0.540 125.882 -0.563
202409 -0.220 126.198 -0.229
202412 -0.230 127.041 -0.238
202503 -0.180 127.779 -0.185
202506 -0.240 128.412 -0.245
202509 -0.240 129.255 -0.244
202512 0.090 129.361 0.091
202603 -0.690 131.258 -0.690

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.10 mean?
Evotec SE (STU:EVT) has a E10 of €-0.10 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Evotec SE and its competitors.
Is Evotec SE's E10 too high?
Evotec SE's current E10 is €-0.10. Overall, Evotec SE has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's E10 compare to ZTS and UTHR?
Evotec SE's E10 of €-0.10 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Evotec SE and its competitors. Evotec SE's current E10 is €-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (STU:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is €7.54, compared to a current price of €4.85 — trading 35.6% below its estimated fair value. The current E10 is €-0.10. Evotec SE's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Evotec SE (STU:EVT), the current E10 is €-0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (STU:EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of €4.85 is trading 35.6% below its estimated GF Value™ of €7.54. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for STU:EVT:

  • E10: €-0.10
  • GF Value™: €7.54 vs. price of €4.85 (35.6% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the STU:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
65GF Score

Get the complete analysis for STU:EVT

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.85
Price
€7.54
GF Value